Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CSX-1004 for fentanyl-induced respiratory depression
NL-OMON60054Phase 2Recruiting
- Sponsor
- Cessation Therapeutics
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of CSX1004 in opioid use disorder (OUD) and opioid-induced respiratory depression (OIRD) (2 arms), sponsored by Cessation Therapeutics. Primary endpoint: Peak change in minute ventilation. Started Mar 2026; status: recruiting.
02
Drugs
CSX1004
03
Conditions
opioid use disorder (OUD)opioid-induced respiratory depression (OIRD)
Beyond the preview
Go deeper on NL-OMON60054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60054.